| Date | Title | Description | |
|---|---|---|---|
| 29 Sep 2025 | On corporate transactions: mergers, acquisitions and others | The Company releases the presentation related to the acquisition of an injectable drug product manufacturing site in Phoenix, Arizona (USA) | Download |
| 29 Sep 2025 | On corporate transactions: mergers, acquisitions and others | ROVI announces the acquisition of an injectable drug product manufacturing site in Phoenix, Arizona (USA) | Download |
| 24 Jul 2025 | On P&L | The Company releases the press release related to the first half of 2025 financial results | Download |
| 24 Jul 2025 | On P&L | The Company releases the first half 2025 financial results presentation | Download |
| 25 Mar 2025 | On business and financial situation | The Company releases the presentation related to its strategy update because of its 2025 Capital Markets Day | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 21 Oct 2021 | Liquidity and counterparty agreements | Download | |
| 21 Oct 2021 | On business and financial situation | The Company informs of the delay in the decision on Risperidone ISM® by the U.S. Food and Drug Administration (“FDA”). | Download |
| 07 Oct 2021 | Liquidity and counterparty agreements | Download | |
| 04 Oct 2021 | Liquidity and counterparty agreements | Download | |
| 01 Sep 2021 | On business and financial situation | ROVI informs about the joint statement from Moderna and Takeda on the investigation of suspended lots of the vaccine | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 21 Feb 2013 | Información sobre resultados (2) | Download | |
| 21 Feb 2013 | Información sobre resultados | Download | |
| 21 Feb 2013 | Informe Anual de Gobierno Corporativo 2012 | Download | |
| 08 Nov 2012 | Información financiera intermedia | Download | |
| 08 Nov 2012 | Información sobre resultados | Download |